TScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Sells $951,885.08 in Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

TScan Therapeutics Stock Down 2.5 %

TCRX opened at $5.53 on Wednesday. The stock’s 50 day moving average price is $6.35 and its 200 day moving average price is $7.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77. The stock has a market cap of $292.33 million, a P/E ratio of -4.32 and a beta of 0.83. TScan Therapeutics, Inc. has a 12 month low of $2.08 and a 12 month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. As a group, research analysts predict that TScan Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Great Point Partners LLC bought a new position in shares of TScan Therapeutics in the second quarter valued at approximately $5,504,000. Tocqueville Asset Management L.P. acquired a new stake in TScan Therapeutics in the first quarter worth approximately $1,685,000. abrdn plc bought a new position in TScan Therapeutics during the 4th quarter valued at $1,166,000. Bank of Montreal Can acquired a new position in shares of TScan Therapeutics during the 2nd quarter valued at $749,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of TScan Therapeutics during the 2nd quarter valued at $682,000. 82.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wedbush restated an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Monday, August 12th. BTIG Research assumed coverage on TScan Therapeutics in a research report on Thursday, May 16th. They set a “buy” rating and a $12.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.